Identification of Key Blood Molecular Markers for Immunotherapy

Terminated

• Conditions: Adenocarcinoma; Neoplasms; Squamous Cell Carcinoma

• Registration Number: NCT00507702
• Lead Sponsor: Stanford University

Brief Summary

To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-07-06
• Study First Submitted: 2007-07-24
• Study First Submitted QC: 2007-07-25
• Study First Posted: 2007-07-26
• Primary Completion: 2015-02-25
• Study Completion: 2015-02-25
• Status Verified: 2019-04
• Last Update Submitted: 2019-04-16
• Last Update Posted: 2019-04-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 191

Inclusion Criteria

1. Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.
2. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.
3. Normal volunteers who do not have cancer or other medical conditions that may affect survival.

Exclusion Criteria

1. Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors.
2. Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered.
3. Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy	3 years

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States